Form 4: SAB Biotherapeutics Secures $40 Million Capital Infusion from Director-Affiliated Fund

An entity affiliated with SAB Biotherapeutics director Andrew Moin has acquired nearly $40 million in convertible preferred stock and warrants, signaling a significant capital infusion for the company.

Summary

• Sessa Capital (Master), L.P., a fund associated with SAB Biotherapeutics director Andrew Moin, acquired Series B Convertible Preferred Stock and accompanying warrants from SAB Biotherapeutics, Inc.
• The aggregate purchase price for the Preferred Stock was $39,987,500.
• The Preferred Stock, totaling 228,500 shares, is convertible into common stock at a price of $1.75 per share, contingent upon stockholder approval.
• The conversion is subject to a beneficial ownership limitation, preventing the Sessa Parties from exceeding 4.99% of the Issuer's outstanding common stock post-conversion.
• The acquisition also included 228,500 Enrollment Warrants (exercisable at $175 per share) and 114,250 Data Release Warrants (exercisable at $218.75 per share), both exercisable until July 21, 2030, or earlier based on specific Phase II dates.

Sentiment

Score: 8

Explanation: The filing indicates a significant capital infusion from an insider-affiliated entity, which is a strong positive signal for the company's financial health and ability to fund its clinical pipeline. The structured warrants tied to clinical milestones further align investor interests with company progress.

Positives

• Significant capital infusion of nearly $40 million into SAB Biotherapeutics, Inc. through the sale of convertible preferred stock and warrants.
• The investment comes from an entity affiliated with a current director, Andrew Moin, which can be interpreted as a vote of confidence from an insider.
• The structure of the warrants (Enrollment and Data Release) ties potential future exercises to key clinical milestones (Phase II Enrollment and Data Release), aligning investor interests with company progress.

Negatives

• The conversion of preferred stock into common stock is contingent on stockholder approval, introducing a potential hurdle for the full realization of the investment's intended structure.
• The beneficial ownership limitation of 4.99% restricts the immediate full conversion of the preferred stock, potentially limiting the investor's direct influence through common stock ownership.

Risks

• Stockholder Approval Risk: The automatic conversion of Series B Convertible Preferred Stock into common stock is contingent upon stockholder approval, which, if not obtained, could alter the investment's intended structure.
• Beneficial Ownership Limitation: The Sessa Parties are limited to converting preferred stock into common stock only up to 4.99% of the Issuer's outstanding common stock, potentially restricting their ability to fully convert their holdings.
• Warrant Exercise Contingencies: The exercisability of the Enrollment Warrants and Data Release Warrants is tied to specific Phase II clinical trial milestones (Enrollment Date and Release Date), introducing uncertainty regarding their timing and value realization.

Future Outlook

The future outlook includes the requirement for SAB Biotherapeutics to obtain stockholder approval for the issuance of common stock upon conversion of the Series B Preferred Stock at a special meeting. Additionally, the exercisability of certain warrants is tied to future clinical milestones, specifically the Phase II Enrollment Date and Phase II Release Date, indicating ongoing progress in their clinical development pipeline.

Management Comments

• Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Industry Context

This transaction represents a significant capital injection for a biotechnology company, SAB Biotherapeutics, which is likely engaged in drug development, given the references to "Phase II Enrollment Date" and "Phase II Release Date." Such funding is crucial for biotech firms to advance their clinical pipelines, especially through costly development stages like Phase II trials. The investment by an affiliated fund of a director suggests confidence in the company's strategic direction and clinical programs, which is a common occurrence in the capital-intensive biotech sector where insider investments can signal strong belief in future success.

Comparison to Industry Standards

• The capital raise of nearly $40 million is a substantial amount for a biotech company, particularly one likely in Phase II clinical development, and compares favorably to many smaller private placements or venture rounds seen in the industry for companies at similar stages.
• The inclusion of warrants tied to clinical milestones (Phase II Enrollment and Data Release) is a common financing structure in biotech, aligning investor incentives with the achievement of scientific progress, similar to milestone-based payments in licensing deals or venture capital rounds for companies like Moderna (pre-IPO) or smaller biotechs securing funding for specific drug candidates.
• The beneficial ownership limitation (4.99%) is a standard provision often included in such agreements to avoid triggering certain regulatory thresholds or change of control provisions, seen in similar investments across the biotech and broader public markets.

Corporate Governance

Related Party Transactions

• The acquisition of Series B Convertible Preferred Stock and warrants by Sessa Capital (Master), L.P. is a related party transaction, as Andrew Moin, a director of SAB Biotherapeutics, Inc., is an Analyst and Partner with the Fund.

Stakeholder Impact

• Shareholders: Potential future dilution upon conversion of the Series B Preferred Stock into common stock, contingent on stockholder approval. The capital raise provides funding for operations, potentially reducing the need for other dilutive financing in the short term.
• Company (SAB Biotherapeutics): Receives a significant capital infusion to fund its operations and clinical development, particularly Phase II trials.

Next Steps

• SAB Biotherapeutics, Inc. needs to hold a special meeting of stockholders to obtain approval for the issuance of common stock upon conversion of the Series B Preferred Stock.
• The company will need to notify the Fund in writing of the Phase II Enrollment Date and Phase II Release Date, which will trigger the exercisability of the respective warrants.

Key Dates

Recommendation

The significant capital injection of nearly $40 million from an insider-affiliated entity, coupled with the director's involvement, signals strong confidence in SAB Biotherapeutics' future prospects and its ability to fund critical clinical trials. This substantial funding reduces immediate financial risk and provides runway for key milestones, making the stock more attractive for long-term growth. The structure of the warrants tied to clinical progress further aligns investor interests with the company's success.

Keywords

SAB Biotherapeutics, SABS, SEC Form 4, Insider Trading, Convertible Preferred Stock, Warrants, Capital Raise, Sessa Capital, Andrew Moin, Biotechnology, Clinical Trials, Phase II, Securities Purchase Agreement